CJC-1295: the long-acting GHRH analogue — 2026 evidence-based guide

The peptide world has a naming problem, and CJC-1295 is perhaps the worst offender. The name refers to two fundamentally different molecules that behave differently in the body, carry different risk profiles, and produce different GH-release patterns — yet they are marketed interchangeably across peptide clinics, forums, and research-chemical suppliers. If you are going to understand this peptide, the first thing you need to grasp is which CJC-1295 anyone is actually talking about.

The molecule itself represents a genuinely clever piece of pharmaceutical engineering: take the bioactive fragment of GHRH, modify it to resist the enzymes that normally degrade it in seconds, and optionally attach it to a system that binds blood albumin to extend its circulation time from minutes to nearly a week. The engineering worked. Whether that engineering translates to a safe and beneficial clinical tool — particularly outside the controlled trial environment — is the question that the 2023 FDA decision and the abandoned development program both leave unresolved.

What is CJC-1295?

CJC-1295 was developed by ConjuChem Biotechnologies (Montreal, Canada) as a long-acting growth hormone releasing hormone analogue. The base molecule is a modified version of GHRH (1-29) — the same bioactive fragment that sermorelin represents — but with four amino acid substitutions at positions 2, 8, 15, and 27 that protect it from dipeptidyl peptidase IV (DPP-IV) cleavage. These modifications extend the half-life from the ~10 minutes of native GHRH to approximately 30 minutes.

The Drug Affinity Complex (DAC) version goes further: a reactive maleimido group is attached that covalently binds to serum albumin after injection. This albumin conjugation extends the effective half-life to 6-8 days, creating sustained GHRH-receptor stimulation from a single weekly injection. This is pharmacologically distinct from the "no-DAC" version (often called Modified GRF 1-29 or MOD-GRF), which behaves much more like a short-acting sermorelin analogue.

How does CJC-1295 work? Mechanism of action

Both versions of CJC-1295 activate the GHRH receptor (GHRHR) on anterior pituitary somatotrophs — the same receptor that sermorelin targets. The receptor activation cascade is identical: Gs protein → adenylyl cyclase → cAMP → PKA → GH gene transcription + granule release. The difference is duration of receptor stimulation.

• CJC-1295 without DAC (MOD-GRF 1-29): Acts for ~30 minutes post-injection. Produces a discrete GH pulse similar to sermorelin but potentially larger due to greater receptor affinity from the amino acid modifications. Somatostatin can still terminate the pulse — physiological regulation preserved
• CJC-1295 with DAC: Albumin-bound, circulates for days. Provides continuous low-level GHRH-receptor stimulation. GH secretion becomes sustained rather than pulsatile. Somatostatin still modulates the output, but the baseline stimulation never fully clears — creating a pattern more similar to pathological GH excess (acromegaly) than normal physiology, albeit at lower magnitude
• DPP-IV resistance: The four amino acid substitutions prevent the enzyme that normally cleaves GHRH at position 2 within seconds. This makes both versions resistant to the primary degradation pathway that limits native GHRH and sermorelin
• Synergy with ghrelin-pathway peptides: CJC-1295 (either version) is frequently combined with ipamorelin or GHRP-6 because GHRH-receptor and GHS-receptor stimulation are synergistic — the combined GH output exceeds the sum of either alone

What does the research say?

Human pharmacokinetic studies (ConjuChem trials)

ConjuChem conducted Phase I and Phase II clinical trials of CJC-1295 with DAC between 2003 and 2006. The Phase I data (Teichman et al., 2006) in healthy adults demonstrated dose-dependent, sustained GH elevation following single subcutaneous injection. At the 60 mcg/kg dose, mean GH levels remained elevated above baseline for 6+ days. IGF-1 rose by 1.5-3x over 2-3 weeks of weekly dosing. The drug was generally well-tolerated in short-term administration.

However, the development program was halted after a subject death occurred during clinical trials. ConjuChem reported that the death was under investigation and the causal relationship to CJC-1295 was unclear — the subject had underlying medical conditions. The program was never resumed, and CJC-1295 with DAC was never submitted for FDA approval. This unresolved safety signal hangs over the molecule and is rarely mentioned in peptide-clinic marketing.

MOD-GRF 1-29 (without DAC) studies

The no-DAC version has less formal clinical trial data as a standalone molecule, though its pharmacology is well-understood from the broader GHRH-analogue literature. It behaves similarly to sermorelin with improved bioavailability and DPP-IV resistance. Most "CJC-1295" research in the peptide-clinic world actually refers to this version, administered subcutaneously 1-3 times daily.

Potential benefits of CJC-1295

The theoretical benefit case for CJC-1295 derives from its GH-elevating properties. As with other secretagogues, claimed benefits are largely extrapolated from GH physiology rather than CJC-1295-specific outcome trials:

• Sustained GH/IGF-1 elevation (DAC version) — The once-weekly dosing convenience was the primary commercial appeal. For patients wanting simplified protocols, the DAC version eliminates daily injections
• Larger GH pulse magnitude (no-DAC version) — The DPP-IV-resistant modifications may produce a larger acute GH surge compared to sermorelin, though direct comparison trials are lacking
• Synergistic with ghrelin-mimetics — When combined with ipamorelin, the dual-receptor stimulation produces GH output exceeding either peptide alone. This "CJC/Ipa" stack was the most popular peptide-clinic protocol prior to 2023
• Body composition support — Elevated GH promotes lipolysis, lean mass preservation, and collagen synthesis. Theoretical rather than proven for CJC-1295 specifically
• Recovery and sleep — Standard GH-pathway benefits. No CJC-1295-specific sleep or recovery trial exists

Dosing protocols discussed in the literature

Side effects and risks

• Injection-site reactions — Redness, swelling, induration at the injection site. Common and generally mild
• Facial flushing and warmth — Acute vasodilation reported within minutes of injection, particularly with the no-DAC version. Self-resolving within 15-30 minutes
• Water retention — Peripheral edema, joint stiffness, carpal-tunnel symptoms. More likely with the DAC version due to sustained GH elevation
• Sustained IGF-1 elevation (DAC version) — The non-pulsatile GH pattern created by the DAC version chronically elevates IGF-1. Epidemiological data associates sustained high IGF-1 with increased risk of colorectal, breast, and prostate cancers. This theoretical risk is the most serious long-term concern
• Unknown contribution to clinical trial death — The unresolved subject death during ConjuChem trials cannot be attributed to or definitively cleared from CJC-1295. This represents a non-trivial unknown in the safety profile
• Quality-control risk (2026) — With Category 2 status severely restricting legitimate access, essentially all CJC-1295 available in 2026 comes from research-chemical suppliers. Purity, sterility, and potency are unverifiable
• Pituitary overstimulation (theoretical) — Chronic GHRH-receptor agonism could theoretically lead to somatotroph hyperplasia or desensitization. No data confirms this with CJC-1295 specifically, but the concern is biologically plausible for the DAC version

Legal and regulatory status (as of April 2026)

CJC-1295 (both versions) was placed on the FDA Category 2 bulk drug substances list in late 2023. This classification indicates that the FDA identified significant safety or quality concerns that make routine 503A compounding inappropriate. The practical consequences:

• Most licensed US compounding pharmacies have stopped compounding CJC-1295
• Any clinic offering CJC-1295 as a standard subscription product in 2026 is either operating under narrow state-specific exemptions or sourcing from unregulated suppliers
• The molecule has never been FDA-approved for any therapeutic indication
• Research-chemical suppliers remain the primary source — with all the quality and safety implications that entails

For patients who were previously on CJC-1295 protocols, the legitimate alternative is sermorelin — which activates the same GHRH receptor, has FDA-approval history, and remains legally compoundable. The GH-elevating effect of sermorelin is shorter-acting and potentially smaller in magnitude, but it is obtainable through the regulated pharmacy system.

What has Huberman Lab said about CJC-1295?

Andrew Huberman has discussed CJC-1295 primarily in the context of the "CJC/Ipamorelin" combination that was widely prescribed by peptide clinics before 2023. In his growth hormone episodes, he explained the GHRH-receptor mechanism and the rationale for combining it with a ghrelin-pathway peptide (ipamorelin) to achieve dual-receptor synergy.

Huberman has drawn an important distinction between the DAC and no-DAC versions — noting that the sustained GH elevation from the DAC variant departs from physiological pulsatility in a way that raises the same theoretical cancer-risk concerns as sustained exogenous GH. His framing has generally favored the no-DAC version (MOD-GRF 1-29) as more physiologically appropriate, though he has acknowledged the regulatory restrictions now limiting access to both.

In post-2023 episodes, the podcast has acknowledged that CJC-1295 is no longer readily available through legitimate channels, and conversations with physician guests have pivoted toward sermorelin as the remaining accessible GHRH-pathway option. Huberman's broader message remains: behavioral GH-optimization tools (sleep, exercise, sauna) should precede pharmacological intervention.

Who might consider CJC-1295?

Given the 2026 regulatory reality, honest consideration of CJC-1295 requires acknowledging that legitimate access is essentially unavailable for most patients. That said, the populations where the pharmacological rationale is strongest include:

• Patients with documented GH insufficiency under specialist endocrinology care who have failed or cannot tolerate other options, and whose clinician has a legal pathway to compounding
• Individuals in clinical research settings where CJC-1295 is being studied under IRB oversight
• Historical context: patients who were previously stable on CJC/Ipa protocols before 2023 restrictions (many have transitioned to sermorelin or ceased peptide use)

Who should not pursue CJC-1295 in 2026: anyone who would need to source it from research-chemical suppliers (which is essentially everyone without a very specific clinical arrangement), patients with cancer history or elevated IGF-1, anyone attracted to the "convenience" of the DAC version without understanding the sustained-IGF-1 implications, or individuals who have not tried the legitimate alternative (sermorelin) first.

Frequently asked questions

Bottom line

CJC-1295 represents a genuine advance in peptide pharmacology — the engineering that produced DPP-IV resistance and albumin-binding is sophisticated, and the PK data confirming sustained GH release is real. But sophistication of design does not equal clinical validation, and the molecule's development history includes an unresolved safety signal (trial death) and a program that was never completed.

In 2026, the practical question is moot for most patients. Category 2 status means legitimate access through US compounding pharmacies is essentially closed. Anyone obtaining CJC-1295 today is overwhelmingly likely sourcing it from unregulated research-chemical suppliers — adding product-quality risk to the already-uncertain biological risk profile. Meanwhile, sermorelin (same receptor target, FDA-approval history, legal compounding access) remains available for patients with legitimate GH-axis concerns.

The CJC/Ipa combination was the flagship product of the pre-2023 peptide-clinic era. That era is over. The patients who benefited most from those protocols now face a choice: transition to the legitimate options that remain (sermorelin, behavioral optimization, or specialist-supervised tesamorelin where indicated), or continue sourcing restricted molecules from unregulated channels. From a risk-benefit standpoint, the former path is the only one we can recommend.

Keep reading

Peptides

Ipamorelin: the selective growth-hormone secretagogue — 2026 evidence-based guide

Peptides

Sermorelin: the original GH-releasing peptide — 2026 evidence-based guide

Peptides

GHRP-6: the original hunger-spiking GH secretagogue — 2026 evidence-based guide